A Comprehensive Review on The Recent Trends in Advancement of Use of Anti-Bacterial Agents

Bacterial infections remain a major global health challenge, driving continuous innovation in antibacterial therapy. Traditional agents such as β-lactams, aminoglycosides, and fluoroquinolones have provided decades of clinical success, yet the rapid emergence of multidrug resistance has significantly reduced their effectiveness. Recent advancements in antibacterial research highlight a paradigm shift toward novel drug classes, innovative delivery systems, and adjunctive approaches. Newer agents including oxazolidinones, pleuromutilins, and glycylcyclines have expanded therapeutic options, while the revival of older drugs such as colistin and fosfomycin demonstrates the strategic re-evaluation of existing molecules. Hybrid molecules and combination therapies are increasingly employed to overcome resistance mechanisms and enhance efficacy. Equally transformative are developments in drug delivery, with nanotechnology-based carriers, liposomal formulations, and controlled release systems enabling targeted action and reduced toxicity. Adjunctive strategies such as antimicrobial peptides, bacteriophage therapy, CRISPR-Cas–mediated antibacterial interventions, and microbiome modulation are gaining prominence as alternatives or complements to conventional drugs. Resistance mitigation remains central, with efflux pump inhibitors, advanced β-lactamase inhibitors, and synergistic adjuvants offering promising solutions. Clinical applications have already demonstrated success in managing multidrug-resistant infections, supported by regulatory initiatives and global antimicrobial stewardship programs. Looking ahead, integration of artificial intelligence in drug discovery, personalised antibacterial therapy, and sustainable approaches through synthetic biology and nanotechnology are expected to redefine the future landscape. This review synthesises recent trends, emphasising the importance of multidisciplinary collaboration to address resistance, optimise therapeutic outcomes, and ensure sustainable antibacterial innovation.